FDA: Seroquel sales aid is misleading

Share this article:
The FDA has asked AstraZeneca to halt distribution of a professional sales aid used to market its antipsychotic medication Seroquel.

In a warning letter sent to AstraZeneca, the FDA's Division of Drug Marketing, Advertising & Communications (DDMAC) wrote that the sales aid is misleading because it minimizes the risk of side effects associated with Seroquel.

“The promotional material raises significant public health and safety concerns through its minimization of the risks associated with Seroquel,” DDMAC wrote.

AstraZeneca spokesman Jim Minnick told MM&M the company was working closely with the FDA to resolve the matter.

“The purpose of the piece was to convey to healthcare professionals accurate and scientifically substantiated information about the risk of diabetes, accompanied by a copy of the FDA approved product information product labeling,” Minnick said.   

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.